Evidence map›Paper›PMID 31186120›Full record

Trial reportLancet (London, England)2019

Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.

Richard Pratley, Aslam Amod, Søren Tetens Hoff, Takashi Kadowaki, Ildiko Lingvay, Michael Nauck, Karen Boje Pedersen, Trine Saugstrup, Juris J Meier, PIONEER 4 investigators

Erratum issued Registry-linked trialAbstract readClinical Trial, Phase IIIComparative StudyMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Lancet (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It reports registered trial NCT02863419. Cited by 267 papers, 29 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
267citing papers in PubMed, 29 pooled it
42.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02863419 phase3completed

Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus

Ran2016Enrolled711Registered outcomes40Posted comparisons14ConditionsDiabetes, Diabetes Mellitus, Type 2Armsliraglutide, Placebo, semaglutide
PMID 35373893PMID 34472698other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

267 citing papers in PubMed, 29 syntheses or guidelines pooled it, 565 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Guideline
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it

207 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 5 countries.

Richard PratleyAdventHealth Translational Research Institute for Metabolism and Diabetes, Orlando, FL, USA. Electronic address: richard.pratley@flhosp.org.
Aslam AmodLife Chatsmed Garden Hospital and Nelson R Mandela School of Medicine, Durban, South Africa.
Søren Tetens HoffNovo Nordisk A/S, Søborg, Denmark.
Takashi KadowakiDepartment of Diabetes and Metabolic Diseases and Department of Prevention of Diabetes and Lifestyle-Related Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Department of Metabolism and Nutrition, Mizonokuchi Hospital, Teikyo University, Kanagawa, Japan.
Ildiko LingvayUniversity of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA.
Michael NauckDiabetes Division, Department of Medicine I, St Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
Karen Boje PedersenNovo Nordisk A/S, Søborg, Denmark.
Trine SaugstrupNovo Nordisk A/S, Søborg, Denmark.
Juris J MeierDiabetes Division, Department of Medicine I, St Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
PIONEER 4 investigators
Novo Nordisk (Denmark) · DKNelson Mandela Academic Hospital · ZARuhr University Bochum · DESt. Josef-Hospital · DETeikyo University · JPThe University of Texas Southwestern Medical Center · USTranslational Research Institute for Metabolism and Diabetes · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlucagon-like peptide-1 (GLP-1) receptor agonists are effective treatments for type 2 diabetes, lowering glycated haemoglobin (HbA

methodsIn this randomised, double-blind, double-dummy, phase 3a trial, we recruited patients with type 2 diabetes from 100 sites in 12 countries. Eligible patients were aged 18 years or older, with HbA

findingsBetween Aug 10, 2016, and Feb 7, 2017, 950 patients were screened, of whom 711 were eligible and randomly assigned to oral semaglutide (n=285), subcutaneous liraglutide (n=284), or placebo (n=142). 341 (48%) of 711 participants were female and the mean age was 56 years (SD 10). All participants were given at least one dose of study drug, and 277 (97%) participants in the oral semaglutide group, 274 (96%) in the liraglutide group, and 134 (94%) in the placebo group completed the 52-week trial period. Mean change from baseline in HbA

interpretationOral semaglutide was non-inferior to subcutaneous liraglutide and superior to placebo in decreasing HbA

fundingNovo Nordisk A/S.

Indexed as

Administration, OralAgedBody WeightDiabetes Mellitus, Type 2Double-Blind MethodFemaleGlucagon-Like PeptidesHumansInjections, SubcutaneousLiraglutideMaleMetforminMiddle AgedSemaglutideTreatment OutcomeGlucagon-Like PeptidesLiraglutideMetforminSemaglutide

Identifiers

PMID31186120
OpenAlexW2948622224

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.